2027年启动IPO！王小川手握30亿现金，ToC医疗产品将发

Group 1 - The core viewpoint of the article is that Baichuan Intelligent, led by CEO Wang Xiaochuan, plans to launch an IPO in 2027, supported by approximately 3 billion yuan in cash, and aims to introduce two consumer-oriented medical products in the first half of this year while simultaneously open-sourcing the next-generation medical large model Baichuan-M3 [1][2] - Baichuan Intelligent's strategy focuses on addressing structural pain points in the medical field, with the ToC medical products designed for serious medical scenarios, initially offered for free to build user trust, followed by monetization through paid modules or partnerships with pharmaceutical and medical device companies [1][2] - The Baichuan-M3 model has achieved a score of 65.1 in the HealthBench evaluation, ranking first globally, with a medical hallucination rate reduced to 3.5%, the lowest in the world, indicating a significant advancement in AI medical applications [2] Group 2 - The transition from general models to a specialized medical vertical marks a strategic shift for Baichuan Intelligent, aiming to facilitate the commercialization of AI in outpatient scenarios and create a more transparent decision-support bridge for patients [2]